Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety ...
Achievement of cancer remission was associated with dermatomyositis complete clinical response among patients with cancer-associated DM.
Treatment with dazukibart, a monoclonal antibody targeting interferon beta, yielded a rapid reduction in dermatomyositis disease activity in adults with skin-predominant and muscle-predominant ...
Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...
Updated 2025 market Reports Released: Trends, Forecasts to 2034 – Early purchase your competitive edge today! LONDON, GREATER LONDON, UNITED KINGDOM, January 30, 2025 /EINPresswire / -- Is the Octagam ...
Hosted on MSN27d
Novel Drug Eases Disease Activity in DermatomyositisThe cause is unknown but may include genetic or environmental triggers. Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...
Immunology: Galapagos has developed treatments for autoimmune diseases ... which is in Phase 2 trials for dermatomyositis and systemic lupus erythematosus (SLE). These programs reflect Galapagos ...
An autoimmune disease crippled his lungs. Hooked up to a machine that oxygenated his blood for him, for 18 months the boy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback